Gilternib Tablets — Gilteritinib 40 mg (90 Tabs) Everest
Gilternib 40 mg (Gilteritinib) is a potent, second-generation FLT3 tyrosine kinase inhibitor and a generic equivalent to Xospata. It is designed to treat aggressive leukemia by targeting specific genetic mutations that drive cancer growth.
Manufacturer: Everest Pharmaceuticals (Bangladesh). Unlike older drugs, Gilteritinib inhibits both FLT3-ITD and FLT3-TKD mutations, offering a broader range of efficacy.
Key Features:
- ✅ Targeted Mechanism: Inhibits FLT3 and AXL receptor signaling, disrupting the proliferation of leukemic cells.
- ✅ Resistant Cases: Specifically formulated for patients whose cancer has returned after or did not respond to initial chemotherapy.
- ✅ Oral Therapy: Convenient tablet form for daily administration.
Notice. The information on this page is for reference only and does not replace medical consultation. Always consult a healthcare professional and read the manufacturer's instructions before using any medicine. Self-medication may be dangerous. Information updated: 21.03.2026
Pack size
What Customers Say
No reviews yet
Your review can be the first!